Slide 1: Presentation to Investors (ASX cover letter)
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au For personal use only Website: www.biotron.com.au 31 March 2011 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (18 pages by email) Dear Madam PRESENTATION TO
Slide 2: March 2011 ASX:BIT
For personal use only March 2011 ASX:BIT
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited and certain of the plans and objectives of its management. These statements are statemen
Slide 4: Biotron Ltd Overview
Biotron Ltd Overview For personal use only • IPO on ASX in Jan 2001 (ASX:BIT); spin out from ANU • Focus on developing novel small molecule antiviral drugs • Hep C, HIV, Dengue • Key highlights • Successful implementation of clinical trials for the Hep C and HIV programs • Successful capital raising
Slide 5: Core Technology
Core Technology For personal use only • Identification of new class of viral proteins – Key roles in production and release of infectious virus – Present in wide range of viruses including influenza ,HIV, Hep C, Dengue and SARS • Ongoing need for new antiviral – viral resistance; – cocktails of anti
Slide 6: BIT's Drug Pipeline
BIT’s Drug Pipeline For personal use only • Two clinical phase programs: – Hepatitis C virus and HIV – Both have very large, expanding world markets • Current status of pipeline: Clinical Trials Project Target Discovery Preclinical Phase I Ph Ib/IIa Ph II PoC Hep C p7 HIV Vpu Dengue M protein + othe
Slide 7: Hepatitis C Virus – The Silent Killer
Hepatitis C Virus – The Silent Killer For personal use only • 170 m people infected worldwide; 4 m patients in US (2.7m chronic infection) • Majority remain asymptomatic for decades before developing cirrhosis or liver cancer • Hepatitis C is one of the most significant public health threats facing
Slide 8: Hep C – An Expanding Market
Hep C – An Expanding Market For personal use only Worldwide market ~US$2.8 billion; predicted to expand to >US$10 billion as new, safer drugs enter the market. Only small percentage currently receive treatment. USA and Europe represent major markets but other, larger markets are emerging. Smith Natu
Slide 9: Hep C Lead Product – BIT225
Hep C Lead Product – BIT225 For personal use only BIT225 is a new investigational oral small molecule drug in development for treating Hep C infection Completed two clinical trials: Phase Ia – 48 patient, single dose safety study in healthy volunteers; Status - completed Phase Ib - 18 patien
Slide 10: Rationale for Phase II Hep C Trial
Rationale for Phase II Hep C Trial For personal use only • Focused on developing saleable product to a pharmaceutical partner(s) • Future Hep C therapies expected to be a cocktail of drugs – In short-term new drugs to be used with current approved drugs interferon (IFN) and ribavirin – Industry focu
Slide 11: Hep C Phase II Combination Trial
Hep C Phase II Combination Trial For personal use only Ph II Trial Period Trial design 0 2 4 Weeks 44 wks BIT225 (400mg) 8 pts + IFN/ribPlacebo Interferon + Ribavirin BIT225 (200 mg) Interferon + Ribavirin 8 pts + IFN/rib BIT225 (400 mg) Interferon + Ribavirin 8 pts + IFN/rib – Pts randomly assigned
Slide 12: Biotron's HIV Clinical Program
Biotron’s HIV Clinical Program For personal use only • First-in-class new anti-HIV drug • New mode of action – inhibits budding of virus from infected cells • Targets HIV in viral reservoirs in vivo • Reservoirs are last of the holy grail in HIV • No existing drugs target this source of HIV in the b
Slide 13: BIT225 Prevents HIV-1 Release from Human Macrophage Reservoirs
BIT225 Prevents HIV-1 Release from Human Macrophage Reservoirs For personal use only Chronic Kinetics d14 infection & d21 BIT225 addition 200 150 Without BIT225 100 +BIT225 50 With BIT225 16 17 19 21 22 23 24 25 26 27 28 Time (days) +HIV-1 Khoury et al., Antimicrobial Agents and Chemotherapy. 2009
Slide 14: Human Reservoirs cells infected with HIV – Untreated and Treated with BIT225
Human Reservoirs cells infected with HIV – Untreated (A) and Treated with BIT225 (B) For personal use only A B Damaged, non- Healthy HIV infectious HIV
Slide 15: BIT225 Reduces HIV-1 Spread within the Reservoir
BIT225 Reduces HIV-1 Spread within the Reservoir For personal use only Monocytes co-cultured with CD4+ T cells for 5 days then separated CD14+ DMSO (Control) P=0.016 CD16+ DMSO (Control) P=0.076 CD14+ BIT225 CD16+ BIT225 HIV-1 (gag DNA) 30000 30000 20000 20000 10000 10000 0 0 2 5 2 5 Time (days)
Slide 16: Investment Summary
Investment Summary For personal use only • Successfully completed TWO human trials of BIT225 • Good safety and efficacy results • Potential to combine with current or next generation Hep C drugs • Strong patent protection – 5 patent families filed worldwide • Antiviral market is very attractive: – P
Slide 17: Capital Structure
Capital Structure For personal use only Shares on issue 121.8 m (pre SPP) Listed options 108 m Unlisted options 6.4 m Cash at 31 Dec 2011 A$0.89 m Market cap (as 30/3/2011) A$14 m Biotron Limited
Slide 18: Dr Michelle Miller, Managing Director
For personal use only Dr Michelle Miller Managing Director +61 2 9805 0488 +61 412 313329 mmiller@biotron.com.au www.biotron.com.au